HC Wainwright restated their buy rating on shares of Oncolytics Biotech (NASDAQ:ONCY – Free Report) in a report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a $5.00 target price on the stock. HC Wainwright also issued estimates for Oncolytics Biotech’s FY2024 earnings at ($0.29) EPS.
Oncolytics Biotech Stock Up 4.2 %
Shares of NASDAQ:ONCY opened at $0.99 on Wednesday. Oncolytics Biotech has a 52-week low of $0.85 and a 52-week high of $2.49. The stock has a market cap of $76.09 million, a price-to-earnings ratio of -3.30 and a beta of 1.91. The business has a 50-day moving average price of $1.01 and a 200-day moving average price of $1.05.
Oncolytics Biotech (NASDAQ:ONCY – Get Free Report) last posted its earnings results on Thursday, August 1st. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. During the same period last year, the business earned ($0.09) EPS. As a group, equities analysts anticipate that Oncolytics Biotech will post -0.29 EPS for the current fiscal year.
Institutional Trading of Oncolytics Biotech
About Oncolytics Biotech
Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.
Featured Stories
- Five stocks we like better than Oncolytics Biotech
- Market Cap Calculator: How to Calculate Market Cap
- Lumen: Among Top Performers Last Month, Still Has Warning Signs
- What are earnings reports?
- Baidu’s Strong Quarter Proves a Smart Pick for Michael Burry
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.